Preclinical studies confirm that GITR activation increases the activity of CD8+ and CD4+ effector T cells and decreases tumour-infiltrating Tregs, particularly in HNSCC. This evidence concerns the gene TNFRSF18 and head and neck squamous cell carcinoma.